Physician

Endocrinology

Dr. Julio Rosenstock, MD

Julio Rosenstock works in the field of Endocrinology. He over the years received 2 awards: "Fellow (FACE)" and "Super Doctor". Dr. Julio Rosenstock is a published physician. He has 23 publications published. The most current publication "The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation. Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies."

Publications

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation. Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 Diabetes: a randomized, placebo-...
GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS.
Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 Diabetes on ...
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 Diabetes management: reflections from a Diabetes ca...
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 Diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, mul...
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 Diabetes inadequately co...
Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine.
Alogliptin versus glipizide monotherapy in elderly type 2 Diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 Diabetes with mild hyperglycaemia.
Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 Diabetes.
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized, Open-Label,...
Cardiovascular outcome trials in type 2 Diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial.
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover s...
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-Emerge 2 Trial.
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 Diabetes.
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes.
Effects of Dapagliflozin, a Sodium-Glucose Cotransporter-2 Inhibitor, on Hemoglobin A1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequate...
Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 Diabetes suboptimally controlled with oral agents.
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist...
Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 Diabetes mellitus insufficiently controlled with basal insulin: analysi...
One-year sustained glycemic control and weight reduction in type 2 Diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c t...

Schools

UNIVERSITY OF COSTA RICA FACULTY OF MEDICINE
Mexico Hospital
Hammersmith Hospital
University Tex Sw Med School

Conditions Treated

Diabetes Type 2
Hyperlipidemia
Hypothyroidism
Lipid Disorders

Doctors Specialties

Endocrinology

Accepted Insurances

Awards

Fellow (FACE)
Super Doctor

Education

Universidad de Costa Rica Faculty of Medicine

Hospital

Medical City Dallas Hospital

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Andrew R. Zinn, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Raphaelle D. Vallera, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan D. Leffert, MD This Doctor is OpenDoctor Recommended.
	Dr. Audrey B. Miklius, MD This Doctor is OpenDoctor Recommended.
	Dr. Philip Raskin, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Polina F. Kaloyanova, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard E. Berger, MD This Doctor is OpenDoctor Recommended.
	Dr. Ugis Gruntmanis, MD This Doctor is OpenDoctor Recommended.